AXDX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East...

Stats
Today's Volume	18 818.00
Average Volume	60 290.00
Market Cap	20.20M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.550 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.190
ATR14	$0.0100 (1.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Phillips Jack	Buy	59 928	Common Stock
2024-04-17	Phillips Jack	Sell	26 735	Common Stock
2024-04-17	Phillips Jack	Sell	59 928	Employee Restricted Stock Units
2024-04-12	Phillips Jack	Buy	59 928	Common Stock
2024-04-12	Phillips Jack	Sell	26 545	Common Stock

INSIDER POWER
96.77
Last 100 transactions
Buy: 51 589 751 \| Sell: 625 027

Accelerate Diagnostics Correlation

10 Most Positive Correlations
VRAY	0.981
ATHX	0.97
ODT	0.968
UXIN	0.962
XPDI	0.961
TCDA	0.96
KSPN	0.943
EBIX	0.941
PLL	0.94
LHDX	0.936

10 Most Negative Correlations
CCRC	-0.969
DSEY	-0.958
DSPG	-0.957
TAST	-0.953
SUMO	-0.95
ORTX	-0.947
FFNW	-0.945
STAY	-0.945
MMAC	-0.943
DUET	-0.942

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Accelerate Diagnostics Financials

Annual	2023
Revenue:	$12.06M
Gross Profit:	$2.55M (21.15 %)
EPS:	$-4.94

FY	2023
Revenue:	$12.06M
Gross Profit:	$2.55M (21.15 %)
EPS:	$-4.94

FY	2022
Revenue:	$12.75M
Gross Profit:	$3.30M (25.90 %)
EPS:	$-7.61

FY	2021
Revenue:	$11.78M
Gross Profit:	$-381 000 (-3.23 %)
EPS:	$-1.260

Financial Reports:

No articles found.

Accelerate Diagnostics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.